New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma
ÌÇÐÄ´«Ã½
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma BLOOD ADVANCES Tandon, N., Sidana, S., Rajkumar, S., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Kapoor, P., Gonsalves, W., Dispenzieri, A., Kourelis, T., Warsame, R., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Hwa, Y., Kyle, R. A., Leung, N., Go, R. S., Lust, J. A., Russell, S. J., Kumar, S. K. 2019; 3 (5): 744–50Abstract
We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with =VGPR and
View details for
View details for
View details for
View details for